Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 23 de marzo del 2007
When AML develops in people over the age of 65, the optimal choice of therapy is debatable. Intensive chemotherapy for AML is highly toxic, and there is great concern over causing more harm than good with this regimen. Many of these patients thus end up treated with a maintenance program of less toxic therapy. This study looked at 54 patients with AML , ages ranging from 66 to 90. Twenty seven patients were treated with an intensive regimen of Fludarabine, Ara-C, and G-CSF (Flag) and mitoxantrone, cytarabine and etoposide (MICE). The median age of these patients was 71 years. Twenty seven patients were treated with maintenance therapy with low dose cytarabine and/or supportive care.
Twelve patients (45%) in the intensive chemotherapy group went into remission in response to treatment, giving an overall survival of 7.15 months. In the group of patients who received maintenance therapy, 30% (eight patients) went into remission and the overall survival was 4.94 months. This difference was not statistically significant.
While this study's authors reported a trend toward improved survival with the intensive chemotherapy, there are some issues with the study's methods. It is not clear if this was a randomized study. It is possible that sicker or more elderly patients were given the maintenance therapy, which would likely make the intensive chemotherapy group appear to have better outcomes. In addition, the toxicities experienced by the groups were not reported, so it is hard to address quality of life issues and the causes of death for the groups. In addition, there are several newer agents being tested and/ or used in older AML patients that should be included in any larger trials looking at therapy for older patients.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults